Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D; “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias” (CETLAM group). Díaz-Santa J, et al. Among authors: zamora l. Eur J Haematol. 2022 Dec;109(6):755-764. doi: 10.1111/ejh.13862. Epub 2022 Sep 16. Eur J Haematol. 2022. PMID: 36063368
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L, Xicoy B, Cabezón M, Fernandez C, Marcé S, Velez P, Xandri M, Gallardo D, Millá F, Feliu E, Boqué C. Zamora L, et al. Leuk Lymphoma. 2015;56(10):2973-4. doi: 10.3109/10428194.2015.1015124. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686645 No abstract available.
Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols.
Ribera J, Morgades M, Zamora L, Montesinos P, Gómez-Seguí I, Pratcorona M, Sarrà J, Guàrdia R, Nomdedeu J, Tormo M, Martínez-Lopez J, Hernández-Rivas JM, González-Campos J, Barba P, Escoda L, Genescà E, Solé F, Millá F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology. Ribera J, et al. Among authors: zamora l. Cancer. 2015 Nov 1;121(21):3809-17. doi: 10.1002/cncr.29579. Epub 2015 Jul 20. Cancer. 2015. PMID: 26194343 Free article.
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Xicoy B, et al. Among authors: zamora l. Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22. Eur J Haematol. 2016. PMID: 26341961
Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.
Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L. Palomo L, et al. Among authors: zamora l. Am J Hematol. 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9. Am J Hematol. 2016. PMID: 26509444 Free article.
Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M, Ribera JM, García O, Cabezón M, Vélez P, Marcé S, Xicoy B, Fernández C, Buch J, Cortes M, Plensa E, Gallardo D, Boqué C, Feliu E, Zamora L. Sorigué M, et al. Among authors: zamora l. Eur J Haematol. 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19. Eur J Haematol. 2016. PMID: 26714837
Feasibility of the AML profiler (Skyline™ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach.
Nomdedéu JF, Puigdecanet E, Bussaglia E, Hernández JJ, Carricondo M, Estivill C, Martí-Tutusaus JM, Tormo M, Zamora L, Serrano E, Perea G, de Llano MPQ, García A, Sánchez-Ortega I, Ribera JM, Nonell L, Aventin A, Solé F, Brunet MS, Sierra J. Nomdedéu JF, et al. Among authors: zamora l. Hematol Oncol. 2017 Dec;35(4):778-788. doi: 10.1002/hon.2304. Epub 2016 May 3. Hematol Oncol. 2017. PMID: 27140599
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Palomo L, et al. Among authors: zamora l. Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937. Oncotarget. 2016. PMID: 27486981 Free PMC article.
CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
Juncà J, Garcia O, Garcia-Caro M, Vila J, Zamora L, Cabezón M, Alonso E, de la Banda E, Rodríguez-Hernández I, Ribera JM, Millá F. Juncà J, et al. Among authors: zamora l. Ann Hematol. 2016 Dec;95(12):1949-1954. doi: 10.1007/s00277-016-2811-y. Epub 2016 Sep 5. Ann Hematol. 2016. PMID: 27595757
348 results